Denosumab

¥600.00¥2,000.00

CAS 号: 615258-40-7
质量标准:>95%,蛋白原液
货号: MB2794

产品简介:

Denosumab is a fully human sequence IgG2 monoclonal antibody that inhibits bone resorption by blocking the activity of receptor activator of nuclear factor-κB ligand (RANKL).
别名:Denosumab;地诺单抗
分子式:C6404H9908N1724O2004S50 分子量:144.71KD
产品形式:蛋白原液。每种装于冻存管中,单抗质量为标示数量1MG或者5MG,体积根据其浓度不同略有不同。
质量标准:
Non-reduced CE-SDS:………………………………………….>90%;
SEC-HPLC:………………………………………………………….>95%;
Bacterial Endotoxins Test:…………………………………. .<10EU/ml
Residual Proteins of Host Cell: ……………………………. <100 ng/mg
Exogenous residual DNA: …………………………………. . <100pg/mg
Residual Protein A: ……………………………………………. .<100 ng/mg
Biological Activity:………………………………………….……. .80% to 125% of standard

储存条件:

-70 ± 15℃for long-term storage, 2-8℃for short-term storage, away from light.

运输条件:

干冰运输

使用建议:

  • meilunbio提供的产品为蛋白原液形式。每种装于冻存管中,单抗质量为标示数量1MG或者5MG,体积根据其浓度不同略有不同。
  • 使用前可以根据自己实验需求进行稀释,溶剂建议用去离子无菌水(meilunbio货号MA0028,去离子无菌水(细胞培养用水))或者PBS(meilunbio货号MA0015PBS(1X),细胞培养级)。
  • 不建议使用含有防腐成分的稀释液进行稀释,会增加细胞或者动物毒性。
  • 稀释前,计算加入多少体积溶剂,请参考购买批次质检单上蛋白浓度,或者询问我司,
  • 举例,质检单显示该批次单抗蛋白原液蛋白浓度为 50mg/ml
    对应5MG包装的蛋白原液体积为5mg(质量)/50mg/ml(浓度)=0.1ML,
    实验需求蛋白浓度为10mg/ml, 需要稀释倍数为 50/10=5, 则需要加入0.4ML,即400ul PBS或者无菌去离子水即可。
    若给药量为固定质量值,比如单次给药0.5MG,对应蛋白原液给药体积为10ul,建议稀释后,提高给药体积降低误差,因为注射器或者移液器吸头残留会影响实验效果。
  • 稀释后的蛋白溶液,可于2-8度冷藏避光保存不超过2周,不建议长期储存。
  • 避免反复冻融,每次冻融蛋白活性会降低约5%左右。
生物活性(仅来自于公开文献,不保证其有效性)
描述 Denosumab is a fully human sequence IgG2 monoclonal antibody that inhibits bone resorption by blocking the activity of receptor activator of nuclear factor-κB ligand (RANKL).
靶点 RANK Ligand
Application Denosumab is a fully human sequence IgG2 monoclonal antibody that inhibits bone resorption by blocking the activity of receptor activator of nuclear factor-κB ligand (RANKL). RANKL is a TNF family protein that is expressed in both secreted and cell surface forms by a variety of bone marrow cell types andmediates bone resorption through its receptor (RANK),which is found on osteoclasts and osteoclast precursors . Denosumab was discovered using XenomouseTM transgenic mice comprising human immunoglobulin genes. The antibody is approved for treatment of postmenopausal women with osteoporosis at high risk for fracture, and for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Denosumab competes directly with bisphosphonates such as alendronic acid in postmenopausal osteoporosis and with zoledronic acid in both of these indications. It has been shown to have comparable efficacy and safety to bisphosphonates with some tolerability and patient acceptability advantages.
美仑相关产品推荐(更多相关靶点抑制剂请详询官网或客服)
产品编号 品名. Target
MB2806 aflibercept VEGFR
MB2786 Alemtuzumab CD52
MB2787 Alirocumab PCSK9
MB2789 Avelumab PDL-1
MB2790 Atezolizumab PDL-1
MB2791 Bevacizumab VEGF
MB2792 Cetuximab EGFR
MB2803 Daratumumab CD38
MB2784 Adalimumab TNF-α
MB2023 Eculizumab 补体蛋白(C5)
MB2795 Etanercept TNF
MB2797 Evolocumab PCSK9
MB2773 Infliximab TNF-α
MB2769 Ipilimumab CTLA-4
MB2772 Matuzumab EGFR
MB2766 Mepolizumab IL-5
MB2767 Nivolumab PD-1
MB2774 Obinutuzumab CD20
MB2776 Ofatumumab CD20
MB2777 Omalizumab IgE
MB2781 Panitumumab EGFR
MB2761 Pembrolizumab PD-1
MB2762 Pertuzumab HER2
MB2763 Ranibizumab VEGFR
MB2938 Ramucirumab VEGFR
MB2749 Rituximab CD20
MB2757 Secukinumab IL-17
MB2751 Tocilizumab/Atlizumab IL-6 receptor
MB2753 Trastuzumab ErbB2
MB2758 Ustekinumab IL-12
规格

1mg, 5mg

相关文档

购物车
滚动至顶部